research Development and Validation of a Reversed-Phase HPLC Method for Simultaneous Determination of Doxazosin Mesylate and Finasteride
Created method to measure doxazosin mesylate and finasteride together.
Search
for
Sort by
Research
480-510 / 1000+ results 
research TGF-β Signaling During the Early Phase of Regeneration Is Required for Wound-Induced Hair Follicle Neogenesis
TGF-β signaling is essential for new hair growth after a wound.
research Response to Ritlecitinib Treatment Based on Salt Improvement Scores in Patients With Alopecia Areata: Post Hoc Analysis of the Allegro Phase 2b/3 Study
Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
research Clinician and Patient Evaluation of Improvement for Eyebrow and Eyelashes Hair Loss During Baricitinib Phase 3 Trials BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
research Alopecia Areata During the Convalescent Phase of Kawasaki Disease
A child's hair loss after Kawasaki disease may help understand the disease's autoimmune causes.
research Health Education England: Stakeholder Summit and Preparations for Phase Two
Health Education England is moving forward with phase two of their cosmetic intervention project after a successful summit and plans for future training standards.
research Results of Stage I in a Phase II Randomized Bilateral Comparison of Bexarotene 1% Topical Gel in Alopecia Areata
Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.
research Dehydroepiandrosterone for Women in the Peri- or Postmenopausal Phase
DHEA may help with sexual function when used intravaginally by menopausal women but is similar to hormone therapy in other aspects and might cause more side effects like acne and hair loss.
research Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen: A Phase III Study of Female Sexual Dysfunction on Testosterone Patch Without Estrogen (APHRODITE)
Testosterone patches can modestly improve sexual function in postmenopausal women not on estrogen therapy.
research Response to Baricitinib in the Treatment of Patients with Early and Late Onset Alopecia Areata in the Phase 2 Portion of BRAVE-AA1 Randomized Controlled Trial
Baricitinib was effective in treating both early and late onset alopecia areata.
research Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials
Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.
research Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the Allegro Phase 2b/3 Study
Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
research Plasmacytoid Dendritic Cells as a Key Player in the Initiation Phase of Alopecia Areata-Induced C3H/HeJ Mouse
Plasmacytoid dendritic cells, which overproduce IFN-α, may play a crucial role in starting alopecia areata, an autoimmune disease causing hair loss.
research A Summary of In Vitro, Phase I, and Phase II Studies Evaluating the Mechanism of Action, Safety, and Efficacy of Clascoterone (Cortexolone 17a Propionate, CB-03-01) in Androgenetic Alopecia
Clascoterone safely promotes hair growth similar to minoxidil.
research Safety and Efficacy of a Topical Treatment (SM04554) for Androgenetic Alopecia: Results from a Phase 1 Trial
Dutasteride more effective than finasteride for hair growth; SM04554 safe and potentially effective for hair loss.
research Baseline Distribution of Eyebrow and Eyelash Loss by Severity of Scalp Hair Loss in Phase 3 Trials of Baricitinib for Alopecia Areata
The document's conclusion cannot be provided because the content is not available.
research PSS20 Mediation Modeling and Measurement Characteristics of the Itch Severity Score from a Phase 2B Trial of Oral CP-690-550 in Patients with Moderate-to-Severe Plaque Psoriasis
CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.
research Impact of Ustekinumab on Quality of Life and Sexual Difficulties Associated with Psoriasis: Results from Phase III Clinical Trials
Ustekinumab significantly improved sexual function and quality of life for people with moderate to severe psoriasis.
research Efficacy and Safety of the Oral Janus Kinase Inhibitor Baricitinib in the Treatment of Adults with Alopecia Areata: Phase 2 Results from a Randomized Controlled Study
Baricitinib is effective and safe for treating severe alopecia areata.
research First-Line Therapy with Gemcitabine and Paclitaxel in Locally Recurrent or Metastatic Breast Cancer: A Phase II Study
Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.
research Proteomic Analysis of Balding and Non-Balding Mesenchyme-Derived Dermal Papilla Cells from Androgenetic Alopecia Patients Using Online Two-Dimensional Reversed Phase-Reversed Phase LC-MS/MS
Found different proteins in balding and non-balding cells, giving insight into hair loss causes.
research Anti-Androgenetic Alopecia Effect of Policosanol from Chinese Wax by Regulating Abnormal Hormone Levels to Suppress Premature Hair Follicle Entry into the Regression Phase
Policosanol helps treat hair loss by balancing hormones and supporting hair growth.
research Evaluation of the Safety and Effectiveness of Intradermal Administration of QR678 Neo Hair Growth Factor Formulation: A Phase-IV, Open-Label, Single-Arm Multi-Ethnicity Clinical Trial
QR678 Neo® is a safe and effective treatment for hair loss in men and women.
research Safety and Biopsy Outcomes of a Topical Treatment (SM04554) for Male Androgenetic Alopecia: Results from a Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Trial
Topical treatment SM04554 safely promotes hair growth in male baldness.
research Efficacy and Safety of Once-Daily Minoxidil Foam 5% Versus Twice-Daily Minoxidil Solution 2% in Female Pattern Hair Loss: A Phase III, Randomized, Investigator-Blinded Study
Once-daily 5% minoxidil foam and twice-daily 2% minoxidil solution are similarly effective and safe for female pattern hair loss.
research Faculty Opinions Recommendation of Hair Regrowth Following a Wnt- and Follistatin-Containing Treatment: Safety and Efficacy in a First-in-Man Phase 1 Clinical Trial
New treatment with Wnt proteins and growth factors safely increases hair thickness.
research Efficacy and Safety of ENERGI-F701 Solution Versus 2% Minoxidil Solution for Female Pattern Hair Loss: A Phase II, Multi-Center, Randomized, Double-Blind, Head-to-Head, Parallel Trial
research Efficacy and Safety of ENERGI-F701 Solution Versus 2% Minoxidil Solution for Female Pattern Hair Loss: A Phase II, Multi-Center, Randomized, Double-Blind, Head-to-Head, Parallel Trial
ENERGI-F701 solution was found to be more effective and safer than Regaine® 2% minoxidil solution in treating female pattern hair loss, with increased hair density and less side effects.
research Faculty Opinions Recommendation of Efficacy and Safety of Topical Finasteride Spray Solution for Male Androgenetic Alopecia: A Phase III, Randomized, Controlled Clinical Trial
research The Selective Androgen Receptor Modulator GTx-024 (Enobosarm) Improves Lean Body Mass and Physical Function in Healthy Elderly Men and Postmenopausal Women: Results of a Double-Blind, Placebo-Controlled Phase II Trial
Enobosarm significantly increased muscle mass and improved physical function in elderly men and postmenopausal women without serious side effects.